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Ataxin-1 Nuclear Localization and Aggregation:
Role in Polyglutamine-Induced Disease
in SCA1 Transgenic Mice
or contracting upon germline transmission. For each
disease, there is a repeat length beyond which the indi-
vidual becomes affected. Generally the critical number
is greater than 40 repeats.
Affected individuals develop pathological characteris-
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tics specific to each disease. For example, HD mainly2 Institute of Human Genetics
compromises the striatum and parts of the cortex, re-3 Department of Biochemistry
sulting in progressive dementia, spasticity, and chorea.4 Department of Neurology
SCA1 involves cerebellar Purkinje cells, inferior olivaryUniversity of Minnesota
cells, and to a variable extent other brainstem nuclei,Minneapolis, Minnesota 55455
causing uncoordinated voluntary movement, impaired5 Department of Neurology
balance, and difficulty speaking and swallowing. OnsetEmory School of Medicine
varies from late adult to juvenile with increasing lengthAtlanta, Georgia 30322
of the tract.6 Departments of Pediatrics, and Molecular
The mechanism of pathogenesis for any of these dis-and Human Genetics
orders remains to be explained. Because SCA1 is domi-Howard Hughes Medical Institute
nant, the expanded form of the protein is expressed asBaylor College of Medicine
well as the unexpanded (Servadio et al., 1995), and theHouston, Texas 77030
absence of ataxin-1 in the mouse does not cause ataxia
(Matilla et al., 1998), work has focused on identifying a
pathogenic gain-in function exerted by the expanded
Summary protein. One approach has been to identify cellular com-
ponents that interact with the disease protein in normal
Transgenic mice carrying the spinocerebellar ataxia and pathological circumstances (Koshy et al., 1996; Col-
type 1 (SCA1) gene, a polyglutamine neurodegenera- omer et al., 1997; Matilla et al., 1997; Wanker et al., 1997).
tive disorder, develop ataxia with ataxin-1 localized to In yeast two-hybrid experiments, the widely expressed
aggregates within cerebellar Purkinje cells nuclei. To glycolytic enzyme GAPDH and the Purkinje-enriched
examine the importance of nuclear localization and leucine-rich acidic nuclear protein (LANP) have been
aggregation in pathogenesis, mice expressing ataxin- shown to bind to ataxin-1. Considering that Purkinje
1[82] with a mutated NLS were established. These cell pathology is a prominent feature of SCA1, LANP is
mice did not develop disease, demonstrating that nu- particularly intriguing as a possible pathogenic cofactor,
clear localization is critical for pathogenesis. In a sec- especially since the interaction is enhanced with longer
ond series of transgenic mice, ataxin-1[77] containing polyglutamine tracts. Furthermore, the LANP protein has
a deletion within the self-association region was ex- been shown to be included in ataxin-1 aggregates in
pressed within Purkinje cells nuclei. These mice devel- transfected cells (Matilla et al., 1997).
Another approach has been to investigate the propen-oped ataxia and Purkinje cell pathology similar to the
sity of these proteins to self-associate and, in particular,original SCA1 mice. However, no evidence of nuclear
to form insoluble aggregates (Ross, 1997). This patho-ataxin-1 aggregates was found. Thus, although nu-
genic mechanism was first proposed (Perutz et al., 1994)clear localization of ataxin-1 is necessary, nuclear ag-
before any such aggregates had been observed in vivo.gregation of ataxin-1 is not required to initiate patho-
Subsequently, aggregates containing the disease pro-genesis in transgenic mice.
tein have been found in HD and SCA1 transgenic mouse
neurons (Davies et al., 1997; Skinner et al., 1997). SimilarIntroduction
nuclear aggregates were also discovered in a SCA1
brain (Skinner et al., 1997), as well as HD (Davies et al.,A number of inherited neurodegenerative diseases in-
1997; DiFiglia et al., 1997), SCA3 (Paulson et al., 1997),volve an expanded polyglutamine repeat within the
and DRPLA brains (Becher et al., 1997). In some dis-coding sequence of the disease gene. This group of
eases, such as SCA1, the aggregates are entirely nu-disorders now includes Huntington disease (HD) (Hun-
clear, while in others, such as HD, they may additionallytington's Disease Collaborative Research Group, 1993),
appear in neurites.spinobulbar muscular atrophy (SBMA) (La Spada, 1991),
It has been suggested that the neuronal aggregatesdentatorubral pallidoluysian atrophy (DRPLA) (Koide et
are the common mechanism of neuropathology for in-al., 1994; Nagafuchi et al., 1994), and the spinocerebellar
herited polyglutamine disorders (Ross, 1997; Davies et
ataxias type 1, 2, 3, 6, and 7 (Orr et al., 1993; Kawaguchi
al., 1998). However, the location of the aggregates does
et al., 1994; Imbert et al., 1996; Pulst et al., 1996; Sanpei not necessarily correlate with the localization of the solu-
et al., 1996; David et al., 1997; Koob et al., 1998). In the ble protein. In Purkinje cells, ataxin-1 is both nuclear
disease allele the repeat tract is unstable, expanding and cytoplasmic (Servadio et al., 1995), while in the
various neuronal types affected in HD, huntingtin is cyto-
plasmic (DiFiglia et al., 1995; Gutekunst et al., 1995;7 To whom correspondence should be addressed (e-mail: harry@
Sharp et al., 1995). Thus, localization of the disease-lenti.med.umn.edu).
8 These authors contributed equally to this work. causing protein to the nucleus may be due either to its
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normal cellular distribution, in the case of ataxin-1, or
to events that are a result of an increase in the number
of glutamines, in the case of huntingtin. The predominant
localization of ataxin-1 to the nucleus of Purkinje cells
in SCA1 transgenic mice (Orr and Zoghbi, 1996; Skinner
et al., 1997) and the occurrence of nuclear alterations
associated with the expression of ataxin-1 with an ex-
panded polyglutamine tract suggest that the primary
site of pathogenesis is nuclear. However, ataxin-1 is
also found in the cytoplasm, and the appearance of
cytoplasmic vacuoles is the first morphological alter-
ation seen in SCA1 transgenic Purkinje cells (Clark et
al., 1997). To determine directly whether the expression
of ataxin-1 with an expanded polyglutamine tract in a
specific cellular compartment is a prerequisite for patho-
genesis in vivo, we created an ataxin-1[82] NLS mutant
that contains a single point mutation, ataxin-1K772T. We
next generated ataxin-1K772T transgenic mice with the
same Purkinje cell-specific regulatory element, Pcp2,
as used by Burright et al. (1995). In a similar fashion, we
developed a second series of SCA1 transgenic mice
containing a deletion within the self-association region
Figure 1. The NLS Containing Lysine 772 Directs Transport of
of ataxin-1 (Burright et al., 1997). In these mice, nuclear Ataxin-1 to the Nucleus in Transiently Transfected COS-1 Cells
aggregates of ataxin-1 failed to form. Mice from both (A) Immunolocalization of ataxin-1K15T to the nucleus in a transfected
series were examined for cellular and behavioral evi- COS-1 cell as assessed by immunofluroescence using the anti-
dence of disease as had been done for the previous ataxin-1 antibody 11750.
(B) Immunolocalization of ataxin-1K772T to the nucleus and cytoplasmSCA1 transgenics.
in a transfected COS-1 cell as assessed by immunofluorescence
using the anti-ataxin-1 antibody 11750.
(C) Immunolocalization to the nucleus of CMPK fused to amino
Results acids 760±816 from ataxin-1 in a transfected COS-1 cell. Subcellular
localization was determined by immunofluorescence using the anti-
Ataxin-1 Contains a Functional NLS FLAG antibody M5.
(D) Immunolocalization to the cytoplasm of CMPK fused to aminoThough NLSs can be quite variable in appearance, many
acids 760±816 from ataxin-1 containing the K772T substitution. Sub-conform to the consensus cluster of arginines and ly-
cellular localization was determined by immunofluorescence usingsines found in SV40 T antigen (Boulikas, 1993). Visual
the anti-FLAG antibody M5.
and computer-aided inspection of the ataxin-1 amino
acid sequence revealed two possible NLSs of this type,
one near the N terminus at lysine 15 and one near the
was still apparent in the nucleus. To verify that lysineC terminus at lysine 772. There was no homology to
772 is indeed part of a functional NLS, a PCR-basedselected unique transport sequences such as the M9
strategy was used to fuse the C-terminal portion ofsequence of hnRNP A1 (Siomi and Dreyfuss, 1995) or
ataxin-1 containing the putative NLS (amino acids 760±to nuclear export sequences (Gerace, 1995).
816) to the cytoplasmic protein chicken muscle pyruvateBoth putative NLSs were separately mutated with a
kinase (CMPK) (Frangioni and Neel, 1993). The C-termi-
single base pair change replacing the lysines at amino
nal ataxin-1/CMPK protein was expressed in the COS-1
acid residues 15 and 772 with threonines, ataxin-1K15T
cells. The result was dramatic; CMPK was totally shifted
and ataxin-1K772T, respectively. This amino acid substitu-
from the cytoplasmic to the nuclear compartment, dem-
tion has been shown to disrupt the function of the SV40 T onstrating that the fused portion of ataxin-1 contained
antigen NLS (Kalderon et al., 1984a, 1984b). The mutated a strong functional NLS (Figure 1C). When the same
cDNA clones were inserted into eukaryotic expression portion of the K772T mutant was fused to CMPK, CMPK
vectors and expressed in COS-1 cells. Indirect immuno- remained completely in the cytoplasm (Figure 1D). This
fluorescence was performed using either the M5 anti- demonstrated that the function of the C-terminal NLS
FLAG monoclonal antibody against a FLAG sequence could be completely abolished with the single K772T
engineered into the N terminus of ataxin-1 or using the substitution.
polyclonal 11750 ataxin-1 antisera directed against a
C-terminal peptide (Servadio et al., 1995). Ataxin-1 local-
ized to the nucleus of transiently transfected COS-1 Ataxin-1K772T Transgenic Mice Express Ataxin-1
cells. When ataxin-1K15T was expressed in COS-1 cells, in the Cytoplasm of Purkinje Cells
it localized to the nucleus suggesting that the N-terminal Mutant ataxin-1 cDNA with 82 CAG repeats was inserted
putative NLS is not necessary for nuclear localization into the Pcp2 Purkinje cell±specific promoter plasmid
(Figure 1A). In contrast to K15T, the K772T mutation pCEVII, used to establish the earlier SCA1 transgenic
did cause a shift in distribution of ataxin-1[82] to the mice (Burright et al., 1995). After implantation of injected
embryos, 94 pups were born, of which 9 were identifiedcytoplasm (Figure 1B). However, substantial staining
Ataxin-1 Nuclear Localization and Aggregation
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Figure 2. SCA1 Ataxin-1K772T Localizes Pre-
dominantly to the Cytoplasm of Transgenic
Mouse Purkinje Cells in Contrast to the
Predominant Nuclear Localization of SCA1
Ataxin-1[82]
(A) A confocal image of SCA1 ataxin-1K772T
localization in Purkinje cells from transgenic
line 772-17. Immunofluorescence was per-
formed using the ataxin-1 antibody 11750.
(B) A confocal image of SCA1 ataxin-1K772T
localization in Purkinje cells from transgenic
line 772-17. Immunofluorescence was per-
formed using the ataxin-1 antibody 11NQ.
(C) A confocal optical section of SCA1
ataxin-1K772T localization in Purkinje cells from
transgenic line 772-17. Immunofluorescence
was performed using the monoclonal anti-
body 1F8 directed to an expanded polyglu-
tamine tract.
(D) A confocal image of SCA1 ataxin-1[82]
localization in Purkinje cells from transgenic
line B05. Immunofluorescence was performed
using the ataxin-1 antibody 11750.
(E) A confocal image of SCA1 ataxin-1[82] localization in Purkinje cells from transgenic line B05. Immunofluorescence was performed using
the ataxin-1 antibody 11NQ.
(F) A confocal optical section of SCA1 ataxin-1[82] localization in Purkinje cells from transgenic line B05. Immunofluorescence was performed
using the monoclonal antibody 1F8 directed to an expanded polyglutamine tract.
as positive for the transgene. Seven founders bred suc- distinguishable from that of nontransgenic mice, with a
slight indication of a diffuse distribution of ataxin-1 incessfully. Southern blot analysis of tail DNA from the
N1 generation revealed that copy number ranged from the cytoplasm and no detectable ataxin-1 in the nucleus
(Figure 1F).1 to 30 among lines. To determine approximate levels
of protein expression, semiquantitative immunofluores- To further examine the level of transgene expression
in the ataxin-1K772T transgenic lines, Northern blottingcence was used. Results showed that the level of
ataxin-1 expression in the Purkinje cells of the ataxin- was performed. Using total cerebellar RNA from 4-week-
old mice, a single band of approximately 3.3 kb (3.1 kb1K772T lines was roughly comparable to that of the SCA1
transgenic line B05. In particular, two ataxin-1K772T trans- in A02 RNA) was detected in transgenic mice (Figure
3A). The density of the bands for 772-17/1, B05/1, andgenic lines, 772-2 and 772-17, accumulated levels of
transgene product somewhat greater than those of the A02/A02 transgene RNA was roughly equal. This is con-
sistent with previous characterization of the A02 andB05 line.
The immunofluorescence analysis also revealed the B05 transgenic lines, where B05/1 was found to express
approximately twice the transgenic RNA of A02/1 (Bur-subcellular distribution of ataxin-1K772T in Purkinje cells
(Figure 2). Despite the fact that in COS-1 cells the mu- right et al., 1995). Since the onset of disease in SCA1
mice depends not only on peak RNA levels, but also ontated protein still entered the nucleus in substantial
amounts, in Purkinje cells ataxin-1K772T was observed to the developmental onset of expression (Burright et al.,
1995), Northern blot analysis was further extended toremain mostly cytoplasmic with no indication of aggre-
gates (Figures 2A-2C). Thus, in contrast to COS-1 cells, 8-, 10-, and 14-day-old 772-2 mice (Figure 3B). Ataxin-
1K772T transgene RNA was clearly detectable at 8 days,in Purkinje cells the NLS at amino acids 771±774 is
the predominant determinant of nuclear localization for which is comparable if not even earlier than previously
reported for the onset of SCA1 RNA in the B05 trans-ataxin-1. Using the N-terminal 11NQ antibody (Skinner
et al., 1997), the C-terminal 11750 antibody, and the genic line.
Ataxin-1 expression was also characterized by West-expanded polyglutamine antibody 1F8 (White et al.,
1997), a similar distribution of ataxin-1K772T within Pur- ern blotting of crude extracts from cerebella of 4- to
5-week-old transgenic mice. Using the 11750 antibodykinje cells was observed. The majority of ataxin-1K772T
was in the cytoplasm. In contrast, B05 transgenic Pur- (Figure 3C), full-length ataxin-1K772T was readily detect-
able in cerebellar extracts prepared from both K772Tkinje cells showed strong nuclear staining for ataxin-1.
In Purkinje cells of B05 transgenic mice, both ataxin-1 transgenic lines. In contrast, full-length ataxin-1 was
barely detectable in cerebellar extracts prepared fromantibodies 11750 and 11NQ showed a strong nuclear
localization of ataxin-1 but with an interesting differ- B05 transgenic mice. The inability to detect by Western
blot the ataxin-1 transgene product in B05 cerebellarence between the two antibodies. With antibody 11750,
ataxin-1 was found diffusely throughout the nucleus as extracts is consistent with earlier observations (Burright
et al., 1995). While the explanation for this remains un-well as in aggregates (Figure 2D). With antibody 11NQ,
ataxin-1 was localized predominantly to nuclear aggre- clear, it strongly suggests that ataxin-1 containing an
expanded number of polyglutamines becomes insolublegates and little diffuse localization was seen (Figure 2E).
Using the 1F8 antibody directed against expanded poly- when expressed in Purkinje cell nuclei. In addition to
the full-length ataxin-1 bands, transgene-specific lowerglutamine tracts, staining of B05 Purkinje cells was barely
Cell
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readily detectable in cerebellar extracts prepared from
A02 mice and both ataxin-1K772T transgenic lines. As with
the Western blot using the 11750 antibody, 11NQ re-
vealed a relatively faint band corresponding to full-
length transgenic ataxin-1 in an extract from a B05
mouse. In contrast to 11750, the transgene-specific
lower molecular weight bands were not detected by
11NQ. Finally, when the blots were probed with the 1F8
antibody (data not shown), the results were identical to
those with 11NQ, except that transgenic ataxin-1[30]
and endogenous murine ataxin-1 were not detected. In
summary, the Western blot data show that full-length
cytoplasmic ataxin-1[82] is extractable while its nuclear
counterpart is not. Amounts of full-length transgenic
ataxin-1 in both of the ataxin-1K772T lines, 772-2 and 772-
17, are comparable to that observed in the A02 ataxin-
1[30] transgenic line. Thus, immunofluroescence, North-
ern, and Western blot analyses all indicate that the level
and cellular pattern of ataxin-1K772T expression are com-
Figure 3. SCA1 Ataxin-1[82]K772T Transgenic Mice Express Trans- parable to the level of transgene expression in the SCA1
gene RNA and Protein at Peak Levels and Developmental Ages that B05 transgenics.
Are Comparable to Those in the B05 SCA1 Ataxin-1[82] Transgenic
Mice
Ataxia-1K772T Transgenic Mice Do Not Develop Ataxia(A) Adult levels of SCA1 transgene RNA in SCA1 ataxin-1[30] homo-
B05 SCA1 transgenic mice become ataxic by home cagezygote A02 transgenic mice (Burright et al., 1995); SCA1 ataxin-
behavior at approximately 12 weeks of age and show1[82] heterozygote B05 transgenic mice (Burright et al., 1995); and
SCA1 ataxin-1[82]K772T transgenic lines 772-17. Levels of GAPDH motor disability by Rotarod testing as early as 5 weeks
mRNA demonstrate equal loading. after birth (Burright et al., 1995; Clark et al., 1997). Both
(B) Expression of SCA1 ataxin-1[82]K772T RNA in transgenic line 772- the home cage ataxia and the Rotarod deficiency are
17 at postnatal days 8, 10, 14, and 28. SCA1 RNA in the ataxin-
progressive, so that by 36 weeks of age B05 mice are1[82] B05 transgenic line is detectable at postnatal day 10 (Burright
severely affected. To compare the neurological statuset al., 1995). The relative level of SCA1 ataxin-1K772T RNA, solid arrow
of ataxin-1K772T mice to B05 mice and to nontransgenichead, to murine Sca1 RNA, open arrow head, in transgenic line 772-
17 is shown. controls, we assessed their Rotarod performance at 12,
(C) A Western blot of cerebellar protein extracts probed with the 20, and 36 weeks of age (Figure 4). At 12 weeks of age,
antibody 11750 directed at C-terminal residues of ataxin-1 (Servadio mean performances for nontransgenic mice and for B05
et al., 1995). Protein extracts were prepared from transgenic cere-
mice closely matched the previously reported resultsbella isolated from SCA1 ataxin-1[30] homozygote A02 transgenic
(Clark et al., 1997). Subsequent comparisons, therefore,mice (Burright et al., 1995). Nontransgenic mice, 1/1; Sca1 homozy-
combined all Rotarod data. Rotatod performances ofgote null mice, 2/2 (Matilla et al., 1998); SCA1 ataxin-1K772T
transgenic lines 772-17 and 772-2; and SCA1 ataxin-1[82] heterozy- 12-week-old 772-17 and 772-2 ataxin-1K772T mice were
gote B05 transgenic mice (Burright et al., 1995). Location of the no different from that of nontransgenic mice. In contrast,
endogenous murine ataxin-1 is indicated by the arrow head. Proteo- B05 performance on the Rotarod was significantly differ-
lytic fragments (70 kDa and 40 kDa) of SCA1 ataxin-1 are seen in
ent from the performance of nontransgenic mice at 12extracts from all transgenic lines (denoted by *).
weeks of age.(D) A Western blot of cerebellar protein extracts probed with the
At 20 weeks of age, B05 mice were significantly moreantibody 11NQ directed at N-terminal residues of ataxin-1 (Skinner
et al., 1997). Protein extracts were prepared from transgenic cere- impaired on the Rotarod than at 12 weeks (Figure 4).
bella isolated from Sca1 homozygote null mice, 2/2 (Matilla et However, there was no significant difference in the Ro-
al., 1998); SCA1 ataxin-1K772T transgenic line 772-17; nontransgenic tarod performance of 772-17 or 772-2 ataxin-1K772T
mice; SCA1 ataxin-1K772T transgenic line 772-2; SCA1 ataxin-1[82]
transgenic mice between 12 and 20 weeks of age. Miceheterozygote B05 transgenic mice (Burright et al., 1995); and homo-
from the ataxin-1K772T 772-2 line were also assessed onzygote SCA1 ataxin-1[30] A02 transgenic mice (Burright et al., 1995).
the Rotarod at 36 weeks. Although the sample size was
small (n 5 2), it was clear that while B05 mice had
molecular weight bands were also visible in protein ex- decreased to a very minimal performance level, 772-2
tracts from each of the SCA1 transgenic lines. However, mice had not and performed as well as age-matched
their size and pattern did not vary with glutamine number control mice. By 36 weeks of age, B05 mice are observed
or cellular localization of ataxin-1. Thus, we concluded by cage behavior to be moderately to severely ataxic,
that these presumably proteolytic fragments of trans- with wide, shuffling gait, and frequent loss of balance
genic ataxin-1 are not related to the ability of the while walking or attempting to stand against the wall of
transgene product to induce disease in mice and most the cage (Burright et al., 1995; Clark et al., 1997). In
likely are the result of overexpressing human ataxin-1 contrast, 772-2 ataxin-1K772T mice failed to display any
in murine Purkinje cells. Nevertheless, they remain an signs of ataxia to at least 1 year of age. Thus, we con-
important consideration in the interpretation of immuno- cluded that ataxin-1K772T transgenic mice do not develop
fluorescence data. the progressive cerebellar dysfunction characteristic of
Western blots were also probed with the 11NQ anti- the B05 SCA1 transgenic mice, despite expressing com-
parable amounts of ataxin-1 in their Purkinje cells.body (Figure 3D). Full-length transgenic ataxin-1 was
Ataxin-1 Nuclear Localization and Aggregation
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Figure 4. Rotard Performance of Ataxin-1K772T
Mice
SCA1 ataxin-1K772T transgenic mice fail to
manifest the progressive loss of neurological
function seen in SCA1 ataxin-1[82] B05
transgenic mice as assessed by the Rotarod.
The graph plots the average performance in
seconds of mice at 12, 20, and 36 weeks of
age on the accelerating Rotarod (Experimen-
tal Procedures) for the four trials on each of
4 sequential testing days. The only perfor-
mance levels found to statistically differ from
those of nontransgenic controls were B05
mice at 12 weeks (p # 0.05), 20 weeks (p #
0.05), and 36 weeks of age (p # 0.05).
Ataxin-1K772T Transgenics Do Not Develop with 30 and 77 glutamines that extended 52 amino acids
into the self-association region (Figure 6A). Yeast two-Significant Purkinje Cell Pathology
Cerebellar sections from 772-17 and 772-2 ataxin-1K772T hybrid analysis demonstrated that ataxin-1 with 77 glu-
tamines, ataxin-1[77]D, containing this deletion were notransgenic mice were stained for calbindin, ataxin-1,
and ubiquitin to determine if any of the cellular changes longer self-associated yet still interacted with LANP
(data not shown).observed in B05 SCA1 mice (Burright et al., 1995; Clark
et al., 1997) were detectable (Figure 5). At 12 weeks of Transfection of COS cells with either the ataxin-1[30]D
(not shown) or the ataxin-1[77]D (Figure 6B) resulted in aage, 772-17 cerebella contained a regular Purkinje cell
layer with no heterotopic cell bodies, no shrinkage of predominantly diffuse nuclear distribution of ataxin-1D.
COS cells transfected with either type of ataxin-1D werethe molecular layer, and no obvious ataxin-1-positive
nuclear or cytoplasmic inclusions (Figure 5B). Cyto- immunoreactive with all three antibodies, 11750, 11NQ,
and 1F8, and ataxin-1D was found to be extractable withplasmic vacuoles were occasionally (approximately 5%)
noted, but far less frequently than in B05 cerebella. Pur- the nuclear matrix (Figure 6C), as had been seen for
ataxin-1[82] (Skinner et al., 1997). However, neither typekinje cells in B05 mice show vacuolation at 3 weeks of
age (Clark et al., 1997), and by 12 weeks of age vacuola- of ataxin-1D molecule formed nuclear aggregates or al-
tered the nuclear distribution of PML, features seen intion is frequent, loss of dendritic arborization is apparent
and accompanied by gliosis and thinning of the molecu- COS cells transfected with intact ataxin-1 (Skinner et
al., 1997). Western blot analysis indicated that eachlar layer, and many cell bodies are displaced from the
Purkinje cell layer (Clark et al., 1997). At 40 weeks of ataxin-1D protein was expressed at a level similar to
that seen in COS cells transfected with ataxin-1[82] (dataage, 772-2 cerebellar histology was still very similar in
appearance to that of nontransgenic mice, with no ap- not shown). These results indicate that the 122±amino
acid sequence deleted in the ataxin-1D constructs mayparent progression of the vacuolation (Figure 5C). In
contrast, many Purkinje cells in 40-week-old B05 mice have a role in the ability of ataxin-1 to form nuclear
aggregates.have died, and surviving cells show a radical loss of
dendritic arborization (Clark et al., 1997; Figure 5D).
Although ataxin-1 aggregates were not detected in Transgenic Mice Expressing Ataxin-1D[77] Do Not
Develop Nuclear Aggregatesataxin-1K772T Purkinje cells, approximately 5% of nuclei
from these cells did contain a faintly or moderately de- To examine if this amino acid region also has a role in
the formation of nuclear aggregates in Purkinje cells, atectable ubiquitin-positive inclusion (data not shown). It
is possible that ataxin-1 is present in these inclusions Pcp2-driven ataxin-1[77]D transgene was constructed
and used to establish two lines of transgenic mice,but is not detectable due to the lower sensitivity of the
ataxin-1 immunofluorescence compared to the ubiquitin ataxin-1[77]D3 and ataxin-1[77]D5. Southern blot analy-
sis indicated that these lines had three and four copiesimmunohistochemistry. In contrast, at 8 weeks of age
75% of B05 Purkinje nuclei contain dense ubiquitinated of the transgene, respectively. Northern blot analysis
revealed that each line expressed transgene RNA at ainclusions that are also strongly ataxin-1-positive.
level comparable to B05 (Figure 7A). Western blot analy-
sis of the 1F8 antibody revealed a transgene-specificA Deletion within the Self-Association Region
of Ataxin-1[77] Alters Its Ability to Form protein band at the appropriate molecular weight for
ataxin-1[77]D (Figure 7B). Thus, in contrast to ataxin-Nuclear Aggregates in COS Cells
Previous studies using the yeast two-hybrid system 1[82], which is not detectable by Western blotting (Bur-
right et al., 1995), ataxin-1[77]D is found in a cerebellaridentified a segment of ataxin-1, between amino acids
495 and 605 in a molecule with 30 glutamines, required protein extract.
The subcellular localization of ataxin-1[77]D was de-for self-association (Burright et al., 1997). To examine
whether this segment has a role in ataxin-1 function, a termined at 3, 5, 8, and 12 weeks of age using the
ataxin-1 antiseras 11750 and 11NQ. At all time points122±amino acid deletion was introduced into ataxin-1
Cell
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Figure 5. Histological Analyses of Ataxin-1K772T Cerebella
Purkinje cells of SCA1 ataxin-1K772T transgenic mice fail to develop the pathological alterations seen in B05 transgenic mice expressing SCA1
ataxin-1[82]. Cerebellar sections were costained with an anti-calbindin antibody (green) and the ataxin-1 antibody 11750 (red).
(A) A cerebellar section from a 12-week-old nontransgenic mouse.
(B) A cerebellar section from a 12-week-old SCA1 ataxin-1K772T 772-17 transgenic mouse showing Purkinje cell morphology identical to that
of the 12-week-old nontransgenic mouse.
(C) A cerebellar section from a 36-week-old SCA1 ataxin-1K772T 772-17 transgenic mouse showing Purkinje cell morphology identical to that
of an age-matched nontransgenic mouse.
(D) A cerebellar section from a 36-week-old SCA1 ataxin-1[82] B05 transgenic mouse demonstrating the severe alterations in Purkinje cells
morphology that develop in these mice (Clark et al., 1997) and are not seen in aged SCA1 ataxin-1K772T transgenic mice.
ataxin-1[77]D localized to the nucleus of Purkinje cells. while a much lower density was evident in the cytoplasm
(Figure 8D). Immunogold particles were evenly dis-However, in contrast to Purkinje cells of B05 mice ex-
pressing ataxin-1[82], those of ataxin-1[77]D transgenic persed throughout the nucleus and were not preferen-
tially localized to any nuclear structures. Immunogoldmice did not form detectable nuclear aggregates (Fig-
ures 8A and 8B). Immunohistochemical analysis using particles were found within the electron-lucent but not
within the electron-dense portions of nucleoli, consis-an antibody to ubiquitin also failed to reveal any indica-
tion of ubiquitinated nuclear aggregates of ataxin-1[77]D tent with free distribution throughout the nucleoplasm.
No fibrillary or filamentous elements suggestive of ag-(Figure 8C).
To examine the subcellular localization of ataxin-1D gregated protein were visualized in either the immu-
nogold material or the unlabeled material with moreat the ultrastructural level, one ataxin-1[77]D3 and one
nontransgenic control mouse at 12 weeks of age were optimal ultrastructural preservation (not shown). Small
clusters of particles were seen, however, that might sug-used for preembedding immunogold electron micros-
copy. As expected from the light microscopic immuno- gest submicroscopic protein aggregation but could also
be a result of the silver intensification procedure. Cyto-cytochemistry, a subset of Purkinje cells from an ataxin-
1[77]D3 animal were labeled with immunogold particles plasmic immunogold particles were dispersed through
the perikarya and were only rarely in direct contact withusing antibody 11750. Nuclei of labeled Purkinje cells
contained a very high density of immunogold particles, organelles or identifiable cytoskeletal elements. They
Ataxin-1 Nuclear Localization and Aggregation
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Figure 6. Subcellular Localization of Ataxin-
1[77]D in Transfected COS Cells
(A) The ataxin-1[77]D construct with the
hatched region indicating the extent of the
amino acid deletion and the boxed region in-
dicating the self-association region (Burright
et al., 1997).
(B) The nuclear distribution (immunoreactivity
with antibody 11750 in green) of ataxin-1 in
COS-1 cells transfected with ataxin-1[77]D
and endogenous PML (red). Scale bar 5 5 mm.
(C) A nuclear matrix preparation from COS-1
cells transfected with ataxin-1[77]D demon-
strating by immunoreactivity the presence of
PML (blue) and ataxin-1 (green). This prepara-
tion was also stained with propidium iodide
(red) to demonstrate the absence of nucleic
acids.
were frequently found, however, to be near cisternea of to the primary antibody and in sections from the non-
transgenic control, indicating a very low level of back-rough endoplasmic reticulum and other areas rich in
free ribosomes. Other Purkinje cells, granule cells, in- ground immunogold labeling. Thus, the ultrastructural
data indicates that even microscopic aggregation doesterneurons, and glia that were examined contained only
rare immunogold particles in proportion to the observed not underlie the neuropathology. It is still possible that
submicroscopic aggregates of ataxin-1 are formed.level of background particles. Immunogold particles
were very rare in sections processed without exposure
Ataxin-1[77]D Transgenic Mice Develop Purkinje
Cell Pathology and Ataxia
Cerebellar sections from ataxin-1[77]D mice were exam-
ined using antibodies to ataxin-1 and the Purkinje cell±
specific protein calbindin. The results of this analysis
revealed a progressive Purkinje cell pathology very simi-
lar to that seen in ataxin-1[82] transgenic mice (Burright
et al., 1997; Skinner et al., 1997). At 3 weeks of age,
cytoplasmic vacuoles were detected that with increas-
ing age became evident in most Purkinje cells (Figure
9A). By 8 weeks of age, shrinkage of the molecular layer
and loss of Purkinje cells proximal dendrites were de-
tected (Figure 9B). At 12 weeks of age, heterotopic Pur-
kinje cell bodies were seen in ataxin-1[77]D mice (Figure
9B). In transgenic mice expressing ataxin-1[82], the
nucleoli of Purkinje cells frequently have an eccentric
nuclear localization (Figure 9C). A similar aberrant local-
ization of nucleoli was found in Purkinje cells of ataxin-
1[77]D mice (Figure 9D). Thus, except for the formationFigure 7. Expression Level of the Ataxin-1[77]D Transgene
of nuclear aggregates of ataxin-1, transgenic mice ex-(A) A Northern blot of cerebellar RNA from ataxin-1[77]D transgenic
mice (77D-3/1 and 77D-5/1), ataxin-1[82] transgenic mice (B05/1), pressing ataxin-1[77]D develop each of the Purkinje
and wild-type FVB mice (1/1) probed with radio-labeled SCA1 cell alterations characteristic of B05 mice expressing
cDNA. Arrowhead indicates the position of endogenous Sca1 RNA ataxin-1[82].
and the arrow transgene RNA. To compare the neurological status of ataxin-1[77]D
(B) A Western blot of cerebellar protein extracts from a 3-week-old
mice to both B05 ataxin-1[82] mice and to nontransgenicataxin-1[77]D3 transgenic mouse (77D-3/1), a wild-type FVB mouse
controls, we assessed their performance on the acceler-(1/1), and a Sca12/2 mouse (2/2) probed with the 1F8 antibody.
Arrow indicates the position of ataxin-1[77]D. ating Rotarod at 12 weeks of age. At 12 weeks of age,
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Figure 8. Ataxin-1[77]D Does Not Form Detectable Aggregates in Transgenic Purkinje Cell Nuclei
(A) A confocal image of a midline sagital cerebellar section from a 12-week-old ataxin-1[77]D3 mouse stained with anti-ataxin-1 antibody
11750. Scale bar 5 5 mm.
(B) A confocal image of a midline sagital cerebellar section from a 12-week-old ataxin-1[77]D3 mouse stained with anti-ataxin-1 antibody
11NQ.
(C) Sections of the cerebellar cortex from a 12-week-old ataxin-1[77]D3 mouse (upper portion) and 12-week-old ataxin-1[82] B05 mouse (lower
portion) stained with a anti-ubiquitin antibody and counterstained with hematoxylin.
(D) An electron micrograph of an immunoreactive Purkinje cell from a 12-week-old ataxin-1[77]D3 transgenic mouse. The nuclear envelope
is marked by an arrow. Immunogold particles (arrowheads) are much more frequent in the nucleus (N) than in the cytoplasm (C). Nuclear
immunogold particles are evenly dispersed and not associated with any normal or abnormal nuclear structures. Scale bar 5 500 mm.
the Rotatod performance of ataxin-1[77]D3 was as com- transfected COS cells, we found that an arginine-lysine
NLS containing lysine 772 was partially responsible forpromised compared to control nontransgenic litter-
mates, as was the performance of B05 ataxin-1[82] mice moving the protein into the nucleus but that another
undefined sequence in ataxin-1 also is important for(Figure 9E). Thus, despite the absence of detectable
nuclear aggregates of ataxin-1, ataxin-1[77]D mice at enabling its transport into that compartment.
In contrast to COS cells, Purkinje cells recognize the12 weeks of age have a pattern of histological and neu-
rological alterations very similar to that seen in B05 C-terminal NLS of ataxin-1 as the major, if not the sole
determinant of ataxin-1 transport into the nucleus. Im-transgenic mice expressing ataxin-1[82].
munofluorescence analysis of ataxin-1K772T expression
in transgenic mouse Purkinje cells demonstrated thatDiscussion
most of the ataxin-1 is located outside of the nucleus,
in the cytoplasm. This altered subcellular distribution ofWe report here data concerning the subcellular traffick-
ing and nuclear aggregation of ataxin-1 in transgenic ataxin-1K772T was seen using antibodies directed to the
carboxy-terminal region, the amino-terminal region, andmouse models of the polyglutamine-induced disease
SCA1 and the pathological consequences of expressing to the expanded polyglutamine tract of ataxin-1 (Figure
2). The difference in ataxin-1K772T distribution in COS cellsa protein with an expanded number of glutamines.
and in Purkinje cells further supports the concept that
the nucleocytoplasmic trafficking of ataxin-1 is regu-Nuclear Localization of Ataxin-1 Is Mediated
by an Arginine-Lysine NLS lated by cell-specific factors. These may operate via
posttranslational modifications of ataxin-1 or throughNucleocytoplasmic transport has become an important
aspect of models explaining the pathogenesis of poly- protein interactions that mask or provide surrogate lo-
calization sequences or act as compartmental anchors.glutamine diseases (Ross, 1997; Davies et al., 1998). For
SCA1, previous data have shown that ataxin-1 has a
complex subcellular distribution involving both the cyto- Nuclear Localization of Ataxin-1[82] Is Required for
Purkinje Cell Pathogenesis in Transgenic Miceplasm and nucleus depending on cell type; in most neu-
rons ataxin-1 is nuclear, but in Purkinje neurons it is One of the hallmarks of polyglutamine disease in hu-
mans is a progressive course that includes cell dysfunc-also partly cytoplasmic, and in nonneuronal cells it is
often entirely cytoplasmic (Servadio et al., 1995). In tion, dysmorphism, and death accompanied by specific
Ataxin-1 Nuclear Localization and Aggregation
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Figure 9. Ataxin-1[77]D Transgenic Mice De-
velop Purkinje Cell Pathology and Ataxia Very
Similar to That Seen in Ataxin-1[82] B05
Transgenic Mice
(A) A confocal z scan of the cerebellar cortex
from a 5-week-old ataxin-1[77]D3 mouse
stained with a calbindin antibody showing
multiple vacuoles (arrows) in Purkinje cell
bodies.
(B) Projected z scans representing 20 mm of
the cerebellar cortex from a 12-week-old
ataxin-1[77]D3 mouse stained with anti-cal-
bindin (green) and anti-ataxin-1 11750 (red)
demonstrating shrinkage of the molecular
layer, loss of proximal dendrites in the Pur-
kinje cells, and heterotopic Purkinje cell
bodies.
(C) A confocal z scan of Purkinje cell nuclei
from a 12-week-old ataxin-1[82] B05 trans-
genic mouse demonstrating eccentric nucleoli
(arrows).
(D) A confocal z scan of Purkinje cell nu-
clei from a 12-week-old ataxin-1[77]D3 trans-
genic mouse demonstrating eccentric nucleoli
(arrows).
(E) The performance deficit of 12-week-old
ataxin-1[77]D3 mice (n 5 8) on the accelerat-
ing Rotarod. Their performance was signifi-
cantly worse (p 5 .0005) than the perfor-
mance of nontransgenic littermates (n 5 12).
neurological symptoms. B05 SCA1 mice, with strong the nuclei of Purkinje cells (Matilla et al., 1997), that
ataxin-1[82] expression alters nuclear structure (Skinnernuclear expression of ataxin-1[82], develop a progres-
sive disease consisting of a series of pathological and et al., 1997), and that mutant ataxin-1 alters the subcellu-
lar localization of the HDJ-2/HSDJ chaperone and 20sneurological alterations, including many morphological
changes found in affected neurons of SCA1 patients, proteosome to the nucleus of SCA1 patient neurons and
SCA1 transgenic mouse Purkinje cells (Cummings etthat is, nuclear aggregate formation, cytoplasmic vacu-
oles, loss of dendritic branching, dislocation of the cell al., 1998). In light of the importance of nuclear localiza-
tion of ataxin-1[82] for development of disease, thesebody into the molecular layer, and overall shrinkage of
the cell, all accompanied by worsening ataxia (Burright proteins are strong candidates for key roles in patho-
genesis.et al., 1995; Clark et al., 1997; Skinner et al., 1997). In
contrast to the B05 mice, ataxin-1K772T transgenic mice, Ataxin-1[82] expressed within the cytoplasm of Pur-
kinje cells is not only nonpathogenic, but also nonag-in which the expression of an expanded form of ataxin-1
is largely restricted to the cytoplasm, show no obvious gregating. The lack of cytoplasmic ataxin-1 inclusions
implies that either this compartment has positive mech-Purkinje cell histopathology or altered neurological phe-
notype. anisms that can ªhandleº large amounts of ataxin-1 with
an expanded number of glutamines, or else it lacks spe-Considering that the ataxin-1K772T transgenic lines 772-2
and 772-17 express the SCA1 transgene at levels com- cific components necessary for aggregate formation.
An example of the former possibility is the compartment-parable to B05 SCA1 mice, it is clear that the NLS muta-
tion K772T has a major impact on the pathogenicity of specific deployment of chaperones, which can reduce
aggregate formation (Cummings et al., 1998), while ex-ataxin-1[82]. The most probable reason for the lack
of disease in the ataxin-1K772T mice is that the major- amples of the latter possibility include LANP or nuclear
matrix proteins (Matilla et al., 1997; Skinner et al., 1997).ity of the protein is unable to enter the nucleus. This
supports the concept that the primary effects of ataxin-1 Another important conclusion to be drawn from the
lack of an overt phenotype in ataxin-1K772T mice is thatwith an expanded glutamine tract occur within the nuclei
of affected cells. This is not entirely unexpected, consid- SCA1 pathogenesis occurs via a protein-, rather than
an RNA-, mediated mechanism. The ataxin-1K772T miceering the recent observations that the ataxin-1-inter-
acting protein LANP is also strongly expressed within express levels of SCA1 mRNA containing an expanded
Cell
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CAG tract comparable to that found in the B05 SCA1 mouse neurons (Davies et al., 1997; Skinner et al., 1997)
transgenic mice. Furthermore, unlike many mRNA con- and in brains from HD (Davies et al., 1997; DiFiglia et al.,
taining nonsense mutations, the K772T mRNA proceeds 1997), SCA3 (Paulson et al., 1997), and DRPLA patients
normally to translation. Yet, in contrast to the B05 SCA1 (Becher et al., 1997) as well as SCA1 patients (Skinner
mice, the ataxin-1K772T fail to develop pathology. Thus, et al., 1997) has lead to the proposal that these nuclear
expression of an mRNA encoding an expanded polyglu- aggregates are the pathological basis for polyglutamine
tamine tract does not cause disease. diseases (Ross, 1997; Davies et al., 1998). Contrary to
this proposal is our demonstration that transgenic mice
Full-Length Ataxin-1 Is Central to SCA1 expressing an ataxin-1D protein with 77 glutamines,
Transgenic Pathogenesis which does not form detectable nuclear inclusions, de-
Proteolysis of the disease protein has been suggested velop a neurological disease very similar to that seen
to play an important role in the pathogenesis of HD in transgenic mice expressing ataxin-1[82], which does
(Mangiarini et al., 1996), MJD/SCA3 (Ikeda et al., 1996), form nuclear aggregates. Thus, the formation of nuclear
DRPLA, and SBMA (Wellington et al., 1998). Western aggregates of ataxin-1 is not required for the initiation
blot analysis of protein extracts from the SCA1 trans- of pathogenesis in this transgenic model. It remains a
genic mice demonstrates that ataxin-1 is also subject possibility that nuclear aggregates of ataxin-1 have a
to proteolysis (Figure 3C). However, an identical pattern role in the progression of disease.
of proteolysis was seen in each of the SCA1 transgenic The importance of ataxin-1 localization to the nucleus
lines, regardless of glutamine repeat number, subcellu- for development of Purkinje cell pathology is dramati-
lar localization, and ultimate pathogenicity of the trans- cally illustrated by the ataxin-1K772T mice. This point is
gene product. Thus, the proteolysis of ataxin-1 does not further exemplified by the extensive overlap in nuclear
appear to be specifically correlated with the develop- alterations seen between Purkinje cells of the ataxin-
ment of disease in SCA1 transgenic mice. More likely, 1[82] and ataxin-1[77]D mice. Even in the absence of
it is the result of overexpressing a human protein in nuclear aggregates, the toxic gain of function of mutant
murine Purkinje cells. Since only the C-terminal-directed ataxin-1 seems to be targeted toward the Purkinje cell
11750 antibody, and not the N-terminal-directed 11NQ nucleus. Using an in vitro cellular model of HD, Saudou
antibody, detect proteolytic fragments of ataxin-1, it ap- et al. (1998 [this issue of Cell]) also showed the impor-
pears that the amino-terminal fragments complemen- tance of nuclear localization for pathogenesis. Interest-
tary to the C-terminal fragments are unstable in Purkinje ingly, these studies further suggested that nuclear ag-
cells. This, and the fact that the N-terminal fragment gregates of a polyglutamine protein are insufficient to
does not include the NLS and is, therefore, identical in induce cell death.
B05 and ataxin-1K772T mice, further suggests that the
Finally, the most obvious conclusion that may be
formation of a toxic polyglutamine-containing segment
drawn from the SCA1 transgenic mice reported here is
of ataxin-1 is not a component of the pathogenic pro-
the importance of the protein context of a polyglutaminecess in the SCA1 transgenic mice.
tract in the pathogenic process. The transgenic modelsIn nuclei of B05 Purkinje cells, and to a lesser extent
of HD (Mangiarini et al., 1996) and MJD/SCA3 (Ikeda etataxin-1K772T Purkinje cells, the diffuse reactivity ob-
al., 1996) used only a small portion of the mutant protein.served with 11750 (Figures 2A and 2D) is most likely
Another recent work involved inserting a polyglutaminedue to the proteolytic fragments seen on 11750 Western
tract into a foreign protein context, hypoxanthine phos-blots. In the case of B05 Purkinje cells, these C-terminal
phoribosyltransferase (Ordway et al., 1997). That all offragments of ataxin-1 enter the nucleus by virtue of the
these mouse lines develop a neurological phenotypeNLS. In the ataxin-1K772T Purkinje cells, the C-terminal
has encouraged the idea that the larger protein contextfragments may enter the nucleus by diffusion. The fact
is irrelevant for pathogenesis. Yet, our data clearly dem-that nuclear aggregates of ataxin-1 in the B05 Purkinje
onstrate that amino acids in ataxin-1 several hundredcells stain intensely with both the 11750 and 11NQ anti-
residues distant from the polyglutamine tract can havebodies (Figures 2D and 2E) suggests they are composed
a critical impact on the cellular biology of the polyglu-mainly of full-length ataxin-1. Thus, these results indi-
tamine protein. While studies of how polyglutaminescate that the initial pathogenic event in SCA1 mice in-
behave outside the context of an intact disease proteinvolves the full-length ataxin-1 protein rather than short
may provide important information, an exploration offragments and occurs at some point between or includ-
pathogenicity in a model predicated on the expressioning nuclear translocation of the protein and its deposi-
of a full-length polyglutamine-disease protein is clearlytion as nuclear aggregates. The inability to detect ex-
essential for a full understanding of the disease process.panded full-length ataxin-1 on Western blots of extracts
from B05 cerebella using either 11NQ or 11750 indicates
that these aggregates are insoluble. Finally, the inability
Experimental Procedures
to detect any form of nuclear ataxin-1 in B05 Purkinje
cells with the 1F8 antibody (Figure 2F) indicates that the Constructs
polyglutamine epitope is unavailable within the nuclear Plasmids for transient transfection consisted of the ataxin-1 cDNA
inserted into the expression vectors pCDNA (Invitrogen) or pSVLaggregates.
(Pharmacia). The FLAG epitope sequence was inserted after the
ataxin-1 start codon using a two-step PCR overlap technique inFormation of Ataxin-1 Nuclear Microscopic
constructs D362±816 and ataxin-1[82]. pSVL[82]K15T and pSVL[82]
Aggregates Is Not Required for the K772T were generated using the same PCR technique to change the
Initiation of SCA1 Pathogenesis AAG codon to ACG (two overlapping primers of opposite orientation,
The finding of neuronal nuclear aggregates of expanded each containing the base change, were used with flanking primers
on an ataxin-1 cDNA template to generate two products overlappingpolyglutamine proteins in HD and SCA1 transgenic
Ataxin-1 Nuclear Localization and Aggregation
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at the relevant codon; these were annealed and used as template comparing fluorescence intensities, collection and processing pa-
rameters were kept constant. For comparing distributions or mor-to generate a large fragment, which was subcloned back into the
cDNA). For the CMPK fusion experiments, a fragment encoding the phologies, parameters were optimized for each image. For quantitat-
ing fluorescence intensity, sections that had been double-stainedstart codon, FLAG sequence, and first nine amino acids of ataxin-1
was subcloned into the 59 polylinker of p3PK (Frangioni and Neel, for ataxin (11750, Cy3) and calbindin (CL-300, Cy5) were scanned
through 20 mm at 2 mm increments with 8-bit pixel depth. The1993). A PCR product encoding amino acids 760±816 of ataxin-1
and tailed with BglII was inserted into the BglII site resulting in scanned area included approximately 10 complete Purkinje cells.
Using the Metamorph software package, the ataxin-1 planes werep3PK-FLAG-C', and the coding region was then transferred to
pCDNA1, which expressed the NLS region of ataxin-1 fused to additively projected to yield a 16-bit image, while the calbindin
planes were projected using maximum value and binarized into aCMPK. Insertion of the corresponding PCR product from K772T
template yielded p3PK-FLAG-K772T. In-frame deletion of amino mask. The mask was applied to the 16-bit ataxin image to eliminate
extracellular staining. Intensity within the cells was summed andacids within the self-association region was accomplished by di-
gesting ataxin-1 cDNA with NcoI, blunting with mung bean nuclease, normalized against endogenous hippocampal ataxin-1 staining in
the same section as an internal control. Results were compareddigesting with PinAI, blunting with Klenow, and religating. Inadver-
tent over-digestion with mung bean nuclease extended the deletion relative to one another to rank the various transgenic lines according
to protein expression level.past the NcoI site, resulting in the construct PS-77-D472±594, and
after subcloning, pSVL[77]D472±594. The transgenes, Pcp2/ataxin-
1K772T and Pcp2/ataxin-1[77]D, were constructed by swapping the
Immunohistochemical Staining of Mouse CerebellumSacII-NdeI fragment of the K772T or the ataxin-1[77]D cDNA into PS-
Immunohistochemistry was performed on 5 mm microtome sections82 (Burright et al., 1995). Both transgene constructs were sequenced
from paraffin-embedded brains. For calbindin staining with CL-300,prior to microinjection.
no unmasking procedure was used. For ubiquitin staining with Ubi-1,
sections were boiled three times for 3±4 min in 0.01 M urea subse-
quent to rehydration. Staining was carried out using the ABCEliteCOS Cell Transfections and Immunofluorescence
kit (Vector); sections were blocked for 20 min in normal serum,As described (Skinner et al., 1997), 80% confluent cells were
incubated for 1 hr at room temperature (CL-300, 1:1000) or overnighttransfected with 5 mg of plasmid DNA using the DEAE-dextran
at 48C (Ubi-1, 1:3000), washed briefly, and incubated for 1 hr at roommethod. Cells were transferred to coverslips, fixed, and stained as
temperature with biotinylated anti-mouseantibodies. These weredescribed (Quinlan et al., 1984), with either M5 (anti-FLAG, 1:100,
washed briefly, incubated with ABC reagent, washed, exposed forKodak) or 11750 (anti-ataxin-1, 1:200). Nuclear matrix preparations
several minutes to DAB substrate, washed, counterstained, dehy-were performed as described (Bisotto et al., 1995). Images were
drated, cleared, and mounted.collected using a confocal microscope (Biorad).
Electron MicroscopyGeneration and Maintenance of Transgenic Mouse Lines
One ataxin-1[77]D3 and one nontransgenic control mouse at 12Transgenes were linearized by digestion with SalI, gel-purified, and
weeks of age, perfused with 4% paraformaldehyde and 0.1% glutar-dialyzed against injection buffer. A 2 mg/ml solution was injected
aldehyde in 0.1 M phosphate buffer (PB), were used for preembed-into FVB embryos, which were implanted into pseudopregnant FVB
ding immunogold electron microscopy. The brains were subse-females. Offspring were screened for presence of the transgene by
quently removed and immersed in the same fixative for 2 hr andSouthern blot or PCR of tail DNA, as described (Burright et al., 1995).
rinsed in 0.1 M PB. Each cerebellum was sectioned at 50 mm usingMice were housed in a conventional facility.
a vibratome. The sections were rinsed with phosphate buffered
saline (PBS), preblocked in with 4% normal goat serum (NGS) in
RNA and Protein Analysis PBS containing 0.05% Triton X-100 for 30 min, and incubated in
For Northern blot analysis, RNA was isolated from whole cerebella the 11750 antibody at 1:500 containing 2% NGS for 48 hr at 48C.
by the acid guanidinium thiocyanate-phenol/chloroform method Sections were rinsed in PBS and incubated overnight in Fab frag-
(Chomczynski and Sacchi, 1987), electrophoresed in the presence ments of goat anti-rabbit secondary antibodies (1:50) conjugated
of glyoxal, blotted, and probed with radiolabeled ataxin-1 cDNA, as to 1.4 nm gold particles (Nanoprobes Inc., Stony Brook, NY) in PBS
described (Burright et al., 1995). For Western blot analysis, whole containing 2% NGS. Sections were rinsed in PBS and fixed in 2%
cerebella were homogenized in lysis buffer (10% glycerol, 5% mer- glutaraldehyde in 0.1M PB for 1 hr. After rinsing in several changes
captoethanol, 2.3% SDS, 0.06 M Tris [pH 6.8]). A portion of the of PB, the gold was silver-intensified as previously described (Yi
crude lysate was heated with loading buffer and electrophoresed, and Hersch, 1997). Sections were postfixed for 10 min in 0.5%
blotted, and probed with 11750 (1:2000), 11NQ (1:2500), 1F8 OsO4 in PB, dehydrated in ascending concentrations of ethanol and
(1:10,000), Ubi 1 (1:3000), or preimmune serum (1:1000), all with propylene oxide, and embedded in Eponate 12 (Ted Pella, Redding,
0.1% Tween-20. After incubating with anti-rabbit or -mouse HRP CA). Semithin sections were stained with toluidine blue for examina-
conjugate, bands were visualized by chemiluminescence (NEN Ren- tion by light microscopy. Ultrathin sections were cut using a Leica
naisance kit). Ultracut S ultramicrotome and collected on uncoated mesh grids.
Grids were stained with uranyl acetate and lead citrate and exam-
ined using an Hitachi H-7500 electron microscope. Since the immu-
Assessment of Motor Ability nogold procedure degrades ultrastructural morphology, sections
Motor ability was assessed using an accelerating Rotarod appara- from each animal that were not subjected to the immunogold proce-
tus, as described (Burright et al., 1997). Mice were given four trials dure were also examined. In addition, background immunogold la-
per day for 4 consecutive days, with 10 min rests between trials. beling was assessed by examining sections processed as above
Each trial lasted until the mouse fell from the rod or for a maximum but not exposed to the primary antibody.
of 10 min. During a trial, the rod accelerated from 4 to 40 rpm over
5 min and then remained at 40 rpm for the remainder of the trial. Data
were analyzed using the SuperANOVA software package (Abacus). Acknowledgments
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